• Syndax Pharmaceuticals granted incoming Chief Financial Officer Aaron A. Ondrey a stock option to purchase up to 270,000 common shares.
• Ondrey’s appointment took effect November 9, 2026. The option carries an exercise price of $9.55 per share.
• The award vests over four years, with 25% vesting on the first anniversary of the vesting commencement date.
• The remaining shares vest in monthly installments of 1/48th over 36 months, subject to continued service through the applicable vesting dates.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611091726PRIMZONEFULLFEED9873817) on November 09, 2026, and is solely responsible for the information contained therein.